Recent Updates
Recently added Catalysts
ARGX

argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

Tuesday, April 11, 2017 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis

Full Press Release Details

argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients.
ShareAdd on Google
Tags: ARGX Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Apr 11, 2017

Biotech snapshot

Lead asset
EmpasiprubartPhase 2
AChR-Ab Seropositive Generalized Myasthenia Gravis →

Catalyst track record

+36%
best trade around ARGX's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for ARGX.

See every catalyst's timing & PoA →